• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CHA2DS2-VASc 评分对经皮冠状动脉介入治疗后急性支架血栓形成的预测和排除价值。

Value of CHA2DS2-VASc Score for Prediction and Ruling Out of Acute Stent Thrombosis After Primary Percutaneous Coronary Intervention.

机构信息

Department of Cardiology, Kahramankazan Hamdi Eriş State Hospital, Ankara, Turkey.

Department of Cardiology, Ankara Abdurrahman Yurtaslan Oncology Education and Research Hospital, Ankara, Turkey.

出版信息

Angiology. 2020 May;71(5):411-416. doi: 10.1177/0003319720903585. Epub 2020 Feb 7.

DOI:10.1177/0003319720903585
PMID:32030991
Abstract

Acute stent thrombosis is an important complication of stent implantation. The CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, previous stroke, vascular disease, age between 65 and 74 years, female gender) score incorporates important cardiovascular (CV) risk factors and predicts prognosis in various CV conditions. We evaluated the value of the CHA2DS2-VASc score in predicting acute stent thrombosis (ie, thrombosis during 24 hours after stent placement) in patients undergoing primary percutaneous intervention for ST-segment elevated myocardial infarction. Patients with intraprocedural stent thrombosis and complications were excluded; 48 (2.1%) of 2732 patients had acute stent thrombosis according to our definition. Median CHA2DS2-VASc score was significantly higher in this stent thrombosis group. Cumulative acute stent thrombosis rates were 0.51% for CHA2DS2-VASc score ≤1, 1.55% for ≤2, 1.80% for ≤3, 2.00% for ≤4, 2.17% for ≤5, and 2.19% for ≤6. The CHA2DS2-VASc score (odds ratio = 1.390, 95% confidence interval = 1.118-1.728; = .003) was an independent predictor of acute stent thrombosis. The CHA2DS2-VASc score ≤1 predicted the absence of the acute stent thrombosis with 91% specificity and 36% sensitivity. Further studies are needed to establish the value of this finding in the context of current clinical practice.

摘要

急性支架血栓形成是支架植入的一个重要并发症。CHA2DS2-VASc(充血性心力衰竭、高血压、年龄≥75 岁、糖尿病、既往卒中、血管疾病、65-74 岁之间、女性)评分纳入了重要的心血管(CV)危险因素,并预测了各种 CV 情况下的预后。我们评估了 CHA2DS2-VASc 评分在预测 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗(PCI)后急性支架血栓形成(即支架置入后 24 小时内发生血栓形成)中的价值。排除了术中支架血栓形成和并发症的患者;根据我们的定义,2732 例患者中有 48 例(2.1%)发生急性支架血栓形成。在该支架血栓形成组中,中位数 CHA2DS2-VASc 评分明显较高。CHA2DS2-VASc 评分≤1 者急性支架血栓形成的累积发生率为 0.51%,≤2 者为 1.55%,≤3 者为 1.80%,≤4 者为 2.00%,≤5 者为 2.17%,≤6 者为 2.19%。CHA2DS2-VASc 评分(比值比=1.390,95%置信区间=1.118-1.728;P=0.003)是急性支架血栓形成的独立预测因子。CHA2DS2-VASc 评分≤1 预测急性支架血栓形成的阴性率为 91%,敏感度为 36%。需要进一步的研究来确定这一发现在当前临床实践中的价值。

相似文献

1
Value of CHA2DS2-VASc Score for Prediction and Ruling Out of Acute Stent Thrombosis After Primary Percutaneous Coronary Intervention.CHA2DS2-VASc 评分对经皮冠状动脉介入治疗后急性支架血栓形成的预测和排除价值。
Angiology. 2020 May;71(5):411-416. doi: 10.1177/0003319720903585. Epub 2020 Feb 7.
2
New CHADS-VASc-HSF score predicts the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.新型 CHADS-VASc-HSF 评分预测 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后无复流现象。
BMC Cardiovasc Disord. 2020 Jul 25;20(1):346. doi: 10.1186/s12872-020-01623-w.
3
Comparison of RCHA2DS2-VASc score and CHA2DS2-VASc score prediction of no-reflow phenomenon in patients with ST-segment elevation myocardial infarction.比较 RCHA2DS2-VASc 评分与 CHA2DS2-VASc 评分对 ST 段抬高型心肌梗死患者无复流现象的预测。
Turk Kardiyol Dern Ars. 2020 Oct;48(7):664-672. doi: 10.5543/tkda.2020.90140.
4
Importance and usage of the CHA2DS2-VASc score in predicting acute stent thrombosis.CHA2DS2-VASc评分在预测急性支架血栓形成中的重要性及应用
Coron Artery Dis. 2016 Sep;27(6):478-82. doi: 10.1097/MCA.0000000000000388.
5
CHA2DS2-VASc score predicts contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction, who have undergone primary percutaneous coronary intervention.CHA2DS2-VASc 评分可预测行直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者的对比剂肾病。
Kardiol Pol. 2018;76(1):91-98. doi: 10.5603/KP.a2017.0177. Epub 2017 Oct 5.
6
Predictive accuracy of CHADS-VASc score in determining the high thrombus burden in patients with non-ST-elevation myocardial infarction.CHADS-VASc 评分预测非 ST 段抬高型心肌梗死患者血栓高负荷的准确性。
Acta Cardiol. 2021 Apr;76(2):140-146. doi: 10.1080/00015385.2019.1707934. Epub 2020 Jan 3.
7
Evaluation of the Predictive Value of CHADS-VASc Score for In-Stent Restenosis.CHADS-VASc评分对支架内再狭窄的预测价值评估
Angiology. 2018 Jan;69(1):38-42. doi: 10.1177/0003319717700746. Epub 2017 Mar 27.
8
CHA2DS2-VASc Score is a Predictor of No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Intervention.CHA2DS2-VASc评分是接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者无复流现象的预测指标。
Angiology. 2016 Oct;67(9):840-5. doi: 10.1177/0003319715622844. Epub 2015 Dec 17.
9
The Predictive Value of CHA2DS2-VASc Score on Residual Syntax Score in Patients With ST Segment Elevation Myocardial Infarction.CHA2DS2-VASc 评分对 ST 段抬高型心肌梗死患者残余Syntax 评分的预测价值。
Arq Bras Cardiol. 2022 Sep;119(3):393-399. doi: 10.36660/abc.20210670.
10
CHA2DS2-VASc score predicts the slow flow/no-reflow phenomenon in ST-segment elevation myocardial infarction patients with multivessel disease undergoing primary percutaneous coronary intervention.CHA2DS2-VASc 评分预测多支血管病变行直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者慢血流/无复流现象。
Medicine (Baltimore). 2021 May 28;100(21):e26162. doi: 10.1097/MD.0000000000026162.

引用本文的文献

1
Effect of Peri-Interventional Blood Loss on In-Stent Thrombosis After Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction.急性心肌梗死患者经皮冠状动脉介入治疗期间失血对支架内血栓形成的影响
J Cardiovasc Dev Dis. 2025 Feb 12;12(2):67. doi: 10.3390/jcdd12020067.
2
Acute Intraprocedural Thrombosis After Flow Diverter Stent Implantation: Risk Factors and Relevance of Standard Observation Time for Early Detection and Management.血流导向装置置入术后即刻急性内漏:早期发现和处理的标准观察时间的风险因素和相关性。
Clin Neuroradiol. 2023 Jun;33(2):343-351. doi: 10.1007/s00062-022-01214-6. Epub 2022 Sep 6.
3
The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
收支平衡成本:经皮冠状动脉介入治疗的房颤患者中加用阿司匹林对净临床影响的观点。
Cardiovasc Drugs Ther. 2024 Jun;38(3):605-619. doi: 10.1007/s10557-022-07367-3. Epub 2022 Jul 13.
4
Predictive Value of CHADS -VASc-HSF Score for Severity of Acute Coronary Syndrome.CHADS-VASc-HSF 评分对急性冠状动脉综合征严重程度的预测价值。
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296211073969. doi: 10.1177/10760296211073969.